Information Provided By:
Fly News Breaks for December 24, 2019
RHHBY, SRPT
Dec 24, 2019 | 07:50 EDT
Credit Suisse analyst Martin Auster lowered his price target for Sarepta (SRPT) to $185 from $190, while reiterating an Outperform rating on the shares after the company announced SRP-9001 ex-U.S. commercial partnership with Roche (RHHBY). The analyst believes Sarepta's deal with Roche provides validation and avoidance of meaningful dilution but reduces ceiling.
News For SRPT;RHHBY From the Last 2 Days
RHHBY
Dec 3, 2021 | 10:16 EST
The Food and Drug Administration announced the approval of Rituxan in combination with chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia. Reference Link
RHHBY
Dec 3, 2021 | 07:34 EST
Roche and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only, or RUO, test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE, VirSNiP SARS-CoV-2 Spike S371L S373P, and VirSNip SARS Spike E484A, the company announced. "The COVID-19 pandemic continues to be an evolving and complex situation, and Roche is committed to responding to healthcare's biggest challenges. The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour. There is still much to learn about Omicron. It's critical to identify Omicron quickly and accurately, which will help inform ongoing research - including the further development of therapeutics and vaccines - and potentially stop or slow down the advance of this new variant," said Thomas Schinecker, CEO Roche Diagnostics.